Literature DB >> 22729559

T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer.

Kathrin Bauer1, Nina Nelius, Miriam Reuschenbach, Moritz Koch, Jürgen Weitz, Gunnar Steinert, Jürgen Kopitz, Philipp Beckhove, Mirjam Tariverdian, Magnus von Knebel Doeberitz, Matthias Kloor.   

Abstract

High-level microsatellite-unstable (MSI-H) colorectal carcinomas (CRC) represent a distinct subtype of tumors commonly characterized by dense infiltration with cytotoxic T cells, most likely due to expression of MSI-H-related frameshift peptides (FSP). The contribution of FSP and classical antigens like MUC1 and CEA to the cellular immune response against MSI-H CRC had not been analyzed so far. We analyzed tumor-infiltrating and peripheral T cells from MSI-H (n = 4 and n = 14, respectively) and microsatellite-stable (MSS) tumor patients (n = 26 and n = 17) using interferon gamma ELISpot assays. Responses against 4 FSP antigens and peptides derived from MUC1 to CEA were compared with and without depletion of regulatory T cells, and the results were related to the presence of the respective antigens in tumor tissue. Preexisting FSP-specific T cell responses were detected in all (4 out of 4) tumor-infiltrating and in the majority (10 out of 14) of peripheral T cell samples from MSI-H CRC patients, but rarely observed in MSS CRC patients. Preexisting T cell responses in MSI-H CRC patients were significantly more frequently directed against FSP tested in the present study than against peptides derived from classical antigens MUC1 or CEA (p = 0.049). Depletion of regulatory T cells increased the frequency of effector T cell responses specific for MUC1/CEA-derived peptides and, to a lesser extent, T cell responses specific for FSP. Our data suggest that the analyzed FSP may represent an immunologically relevant pool of antigens capable of eliciting antitumoral effector T cell responses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22729559     DOI: 10.1007/s00262-012-1303-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

Review 1.  Targeting cancer-specific mutations by T cell receptor gene therapy.

Authors:  Thomas Blankenstein; Matthias Leisegang; Wolfgang Uckert; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2015-02-27       Impact factor: 7.486

2.  Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer.

Authors:  Fabian Echterdiek; Jonas Janikovits; Laura Staffa; Meike Müller; Bernd Lahrmann; Monika Frühschütz; Benjamin Hartog; Nina Nelius; Axel Benner; Mirjam Tariverdian; Magnus von Knebel Doeberitz; Niels Grabe; Matthias Kloor
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

3.  Novel Proteome Extraction Method Illustrates a Conserved Immunological Signature of MSI-H Colorectal Tumors.

Authors:  Elez D Vainer; Juliane Kania-Almog; Ghadeer Zatara; Yishai Levin; Gilad W Vainer
Journal:  Mol Cell Proteomics       Date:  2020-07-08       Impact factor: 5.911

4.  Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:  D Scott McMeekin; David L Tritchler; David E Cohn; David G Mutch; Heather A Lankes; Melissa A Geller; Matthew A Powell; Floor J Backes; Lisa M Landrum; Richard Zaino; Russell D Broaddus; Nilsa Ramirez; Feng Gao; Shamshad Ali; Kathleen M Darcy; Michael L Pearl; Paul A DiSilvestro; Shashikant B Lele; Paul J Goodfellow
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

Review 5.  Genetic Screening and Personalized Prevention in Colorectal Cancer.

Authors:  Verena Steinke-Lange; Elke Holinski-Feder
Journal:  Visc Med       Date:  2019-07-17

6.  Intratumoral density of regulatory T cells is a predictor of host immune response and chemotherapy response in colorectal cancer.

Authors:  Masanori Oshi; Joy Sarkar; Rongrong Wu; Yoshihisa Tokumaru; Li Yan; Kazuya Nakagawa; Atsushi Ishibe; Ryusei Matsuyama; Itaru Endo; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

7.  Cellular vaccination of MLH1-/- mice - an immunotherapeutic proof of concept study.

Authors:  Claudia Maletzki; Yvonne Saara Gladbach; Mohamed Hamed; Georg Fuellen; Marie-Luise Semmler; Jan Stenzel; Michael Linnebacher
Journal:  Oncoimmunology       Date:  2017-12-14       Impact factor: 8.110

Review 8.  Towards a vaccine to prevent cancer in Lynch syndrome patients.

Authors:  Magnus von Knebel Doeberitz; Matthias Kloor
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 9.  Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate.

Authors:  Jason A Willis; Laura Reyes-Uribe; Kyle Chang; Steven M Lipkin; Eduardo Vilar
Journal:  Clin Cancer Res       Date:  2019-08-05       Impact factor: 12.531

Review 10.  Genetic and biological hallmarks of colorectal cancer.

Authors:  Jiexi Li; Xingdi Ma; Deepavali Chakravarti; Shabnam Shalapour; Ronald A DePinho
Journal:  Genes Dev       Date:  2021-06       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.